Time filter

Source Type

Amsterdam-Zuidoost, Netherlands

van Amerongen B.M.,VU University Amsterdam | van Amerongen B.M.,Academic Center for Dentistry | Feron F.,Aix - Marseille University
International Journal of Molecular Sciences | Year: 2012

Mounting evidence correlate vitamin D3 (cholecalciferol) supplementation or higher serum levels of vitamin D (25(OH)D) with a lower risk of developing multiple sclerosis (MS), reduced relapse rate, slower progression or fewer new brain lesions. We present here the case of a woman who was diagnosed with MS in 1990. From 1980 to 2000, her ability to walk decreased from ~20 to 1 km per day. Since January 2001, a vitamin D3 supplement was ingested daily. The starting dose was 20 mcg (800 IU)/day and escalated to 100 mcg (4000 IU)/day in September 2004 and then to 150 mcg (6000 IU)/day in December 2005. Vitamin D3 intake reduced muscular pain and improved ambulation from 1 (February 2000) to 14 km/day (February 2008). Vitamin D intake over 10 years caused no adverse effects: no hypercalcaemia, nephrolithiasis or hypercalciuria were observed. Bowel problems in MS may need to be addressed as they can cause malabsorption including calcium, which may increase serum PTH and 1,25(OH)2D levels, as well as bone loss. We suggest that periodic assessment of vitamin D3, calcium and magnesium intake, bowel problems and the measurement of serum 25(OH)D, PTH, Ca levels, UCa/Cr and bone health become part of the integral management of persons with MS. © 2012 by the authors; licensee MDPI, Basel, Switzerland. Source

Nikolopoulou M.,Academic Center for Dentistry
Journal of orofacial pain | Year: 2013

To assess the influence of occlusal stabilization splints on sleep-related respiratory variables in obstructive sleep apnea (OSA) patients. Ten OSA patients (47.3 ± 11.7 years of age) received a stabilization splint in the maxilla. All patients underwent three polysomnographic recordings with their splint in situ, and three recordings without their splint in situ, using a randomized crossover design. Repeated-measures ANOVAs did not yield statistically significant differences in the Apnea-Hypopnea Index (AHI) or in the Epworth Sleepiness Scale (ESS), neither between the three nights without the stabilization splint (AHI: F = 2.757, P = .090; ESS: F = 0.153, P = .860) nor between the nights with the splint in situ (AHI: F = 0.815, P = .458; ESS: F = 0.231, P = .796). However, independent ANOVAs revealed that the mean AHI of the three nights with the stabilization splint in situ (17.4 ± 7.0 events/hour) was significantly higher than that of the nights without the splint in situ (15.9 ± 6.4 events/hour) (F = 7.203, P = .025). The mean increase in AHI with the splint in situ was 1.4 ± 1.7 (95% confidence interval = -1.9-4.7). No difference in ESS was found when both conditions were compared (F = 1.000, P = .343). The use of an occlusal stabilization splint is associated with a risk of aggravation of OSA; however, the effect size was small, which reduces the clinical relevance of the study. Source

van der Meulen M.J.,Academic Center for Dentistry
Journal of orofacial pain | Year: 2010

To examine temporomandibular disorder (TMD) patients' illness beliefs and self-efficacy in relation to bruxism, and to examine whether these beliefs are related to the severity of patients' self-perceived bruxing behavior. A total of 504 TMD patients (75% women; mean age ± SD: 40.7 ± 14.6 years), referred to the TMD Clinic of the Academic Centre for Dentistry Amsterdam, completed a battery of questionnaires, of which one inquired about the frequency of oral parafunctional behaviors, including bruxism (clenching and grinding). Patients' illness beliefs were assessed with a question about the perceived causal relationship between bruxism and TMD pain; patients' self-efficacy was assessed with questions about the general possibility of reducing oral parafunctional behaviors and patients' own appraisal of their capability to accomplish this. Sleep bruxism or awake bruxism was attributed by 66.7% and 53.8% of the patients, respectively, as a cause of TMD pain; 89.9% believed that oral parafunctions could be reduced, and 92.5% believed themselves capable of doing so. The higher a patient's bruxism frequency, the more bruxism was believed to be the cause of TMD pain (Spearman's rho 0.77 and 0.71, P < .001) and the more pessimistic the self-efficacy beliefs were about the reducibility of oral parafunctions (Kruskal-Wallis ?2 = 19.91, df = 2, P < .001; and Kruskal-Wallis ?2 = 7.15, df = 2, P = .028). Most TMD patients believe in the harmfulness of bruxism and the possibility of reducing this behavior. Bruxism frequency is associated with illness beliefs and self-efficacy. Source

Kalaykova S.I.,Academic Center for Dentistry
Journal of orofacial pain | Year: 2011

To test the hypothesis that oral parafunctions and symptomatic temporomandibulair joint (TMJ) hypermobility are risk factors in adolescents for both anterior disc displacement with reduction (ADDR) and intermittent locking. Participants were two hundred sixty 12- to 16-year-old adolescents (52.3% female) visiting a university clinic for regular dental care. ADDR and symptomatic TMJ hypermobility were diagnosed using a structured clinical examination. During the anamnesis, reports of intermittent locking and of several parafunctions were noted, eg, nocturnal tooth grinding, diurnal jaw clenching, gum chewing, nail biting, lip and/or cheek biting, and biting on objects. The adolescents' dentitions were examined for opposing matching tooth-wear facets as signs of tooth grinding. Risk factors for ADDR and intermittent locking were first assessed using univariate logistic regression and then entered into a stepwise backward multiple model. While in the multiple model, ADDR was weakly associated only with increasing age (P = .02, explained variance 8.1%), intermittent locking was weakly correlated to diurnal jaw clenching (P = .05, explained variance 27.3%). In adolescence, diurnal clenching may be a risk factor for intermittent locking while age may be a risk factor for ADDR. Symptomatic TMJ hypermobility seems to be unrelated to either ADDR or to intermittent locking. Source

Turksma A.W.,VU University Amsterdam | Braakhuis B.J.,VU University Amsterdam | Bloemena E.,VU University Amsterdam | Bloemena E.,Academic Center for Dentistry | And 3 more authors.
Immunotherapy | Year: 2013

Head and neck squamous cell carcinoma is the sixth most common cancer in the western world. Over the last few decades little improvement has been made to increase the relatively low 5-year survival rate. This calls for novel and improved therapies. Here, we describe opportunities in immunotherapy for head and neck cancer patients and hurdles yet to be overcome. Viruses are involved in a subset of head and neck squamous cell carcinoma cases. The incidence of HPV-related head and neck cancer is increasing and is a distinctly different disease from other head and neck carcinomas. Virus-induced tumors express viral antigens that are good targets for immunotherapeutic treatment options. The type of immunotherapeutic treatment, either active or passive, should be selected depending on the HPV status of the tumor and the immune status of the patient. © 2013 Future Medicine Ltd. Source

Discover hidden collaborations